Kite Pharma Inc. (KITE) 70.32 $KITE Critical Al
Post# of 273322
Posted On: 07/29/2015 1:38:55 PM
Kite Pharma Inc. (KITE) 70.32 $KITE
Critical Alerts For Palo Alto Networks, Intrexon, FireEye, Mylan and Kite Pharma Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PANW, XON, FEYE, MYL and KITE.
FEYE: 46.89 (+1.20), KITE: 70.32 (-1.59), XON: 59.83 (-0.77), MYL: 57.09 (+0.74), PANW: 182.40 (-4.43)
NantKwest Surges As Biggest Biotech Market Cap IPO
at Investor's Business Daily - Tue Jul 28, 11:08AM CDT
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 70.32 (-1.59), NK: 35.78 (+1.14), ALXN: 201.73 (-1.82), RCPT: 227.77 (+0.61), AMGN: 169.92 (-2.82), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 35.46 (-0.85), BIIB: 310.86 (-9.07), BBC: 35.81 (-0.86), ADRO: 26.34 (-0.24), KITE: 70.32 (-1.59), NK: 35.78 (+1.14), ALXN: 201.73 (-1.82), RCPT: 227.77 (+0.61), TEVA: 71.10 (-0.31), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
3 IPOs That Are Getting Strong Investor Attention
at Investor's Business Daily - Wed Jul 15, 11:48AM CDT
With strong investor demand for shares, ProNAi Therapeutics (DNAI) raised the expected price of its initial public offering, which is scheduled to price after the close Wednesday. ProNAi is among three of the eight IPOs out this week that are...
RPD: 24.61 (-0.41), CYBR: 58.28 (-1.55), KITE: 70.32 (-1.59), OLLI: 19.59 (-0.12), DNAI: 26.53 (-0.28), QLYS: 36.75 (-0.38), JUNO: 48.08 (-0.54)
'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 96.01 (+0.72), FBT: 124.21 (-2.39), XBI: 251.67 (-7.27), AMGN: 169.92 (-2.82), IBB: 375.98 (-6.86), INTC: 29.03 (+0.07), CELG: 132.89 (-2.53), NFLX: 106.61 (-0.29), SPY: 210.27 (+0.94), GILD: 116.69 (+3.62), KITE: 70.32 (-1.59), RCPT: 227.77 (+0.61), JUNO: 48.08 (-0.54), TWTR: 31.50 (-5.04), AAPL: 122.70 (-0.68), Z: 79.15 (-1.04)
Critical Alerts For Cliffs Natural Resources, JD.com, Kite Pharma, JetBlue and Amazon.com Released By InvestorsObserver
PR Newswire - Tue Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CLF, JD, KITE, JBLU and AMZN.
AMZN: 527.05 (+1.02), KITE: 70.32 (-1.59), JBLU: 22.90 (+0.08), CLF: 2.89 (-0.08), JD: 32.92 (+0.44)
Trader's Notebook: Can Chevron Maintain Its High Yield?
at The Street - Tue Jul 14, 8:00AM CDT
Look under the hood when considering when to make a play for higher yielding names.
KITE: 70.32 (-1.59), CVX: 92.83 (+0.43)
5 Stocks Ready for Breakouts -- Must-See Charts
at The Street - Fri Jul 10, 8:35AM CDT
These stock charts look ready to break out and trade higher from current levels.
VSTM: 7.51 (-0.12), KITE: 70.32 (-1.59), GKOS: 32.10 (+1.33), AMRN: 2.21 (+0.06), CTCT: 24.79 (-0.42)
3 Biotech Stocks Working On CAR-T Immunotherapy You Ought To Watch
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 06, 12:02PM CDT
Source: Juno Therapeutics. Last week, Celgene Corp. shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics ' stock and a handful of licensing rights, leaving Celgene with a 10% stake in the...
ZIOP: 12.45 (-0.19), KITE: 70.32 (-1.59), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
InsiderInsights.com Daily Round Up 7/2/15: NHF, VISI, NXRT, ATLS
InsiderInsights - at Seeking Alpha - Sat Jul 04, 11:54AM CDT
LBTYK: 48.60 (-0.09), TACO: 15.37 (+0.03), ATLS: 3.32 (+0.25), GIII: 68.92 (-0.42), VISI: 9.50 (-0.12), NXRT: 12.73 (-0.08), ALRM: 17.75 (+0.67), TRU: 24.92 (+0.32), W: 36.13 (-1.73), LVLT: 49.41 (-3.09), PDVW: 29.05 (-1.37), COF: 79.11 (+0.46), KITE: 70.32 (-1.59), APPF: 14.52 (-0.18), CPLA: 51.24 (+0.99), HRG: 13.99 (+0.32), JUNO: 48.08 (-0.54), TWTR: 31.50 (-5.04)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 156.39 (-3.93), KITE: 70.32 (-1.59), ADMS: 25.23 (-1.31), ACHN: 8.41 (unch)
Celgene: The Juno Therapeutics Deal Is Worth The Premium
LN Investors - at Seeking Alpha - Wed Jul 01, 3:04PM CDT
KITE: 70.32 (-1.59), AMGN: 169.92 (-2.82), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53), NVS: 103.81 (+1.02)
Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
GlobeNewswire - Wed Jul 01, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
KITE: 70.32 (-1.59)
'Fast Money' Recap: Greece's Uncertain Future Extends to U.S. Stocks
at The Street - Wed Jul 01, 4:00AM CDT
The trading panel discussed Puerto Rico, European stocks and whether Facebook will buy Twitter.
FIT: 44.66 (-0.81), SPY: 210.27 (+0.94), NKE: 114.39 (+0.92), KITE: 70.32 (-1.59), GILD: 116.69 (+3.62), FB: 96.01 (+0.72), DB: 33.46 (+0.22), GOOGL: 654.47 (-5.19), KORS: 39.59 (+0.17), TWTR: 31.50 (-5.04), AAPL: 122.70 (-0.68)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 156.39 (-3.93), KITE: 70.32 (-1.59), CLLS: 35.73 (-0.65), JUNO: 48.08 (-0.54), CYAD: 57.09 (+0.25), CELG: 132.89 (-2.53)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)
Why Juno Therapeutics Stock Soared Today
George Budwell, The Motley Fool - Motley Fool - Tue Jun 30, 10:35AM CDT
What : Shares of the clinical-stage biopharma Juno Therapeutics jumped by 33% on exceptionally high volume today after the company announced a 10-year licensing agreement with Celgene Corp. for its CAR-T and TCR drug development platform. Per...
NBL: 36.08 (+0.58), KITE: 70.32 (-1.59), AZN: 32.94 (+0.13), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
I Don't Believe This Correction Is Over
at The Street - Tue Jun 30, 9:20AM CDT
There just is no certainty and there's very little trust.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT
FIT: 44.66 (-0.81), PIRS: 3.12 (-0.08), KITE: 70.32 (-1.59), SRPT: 31.50 (-0.53), WSH: 46.60 (+0.41), CALA: 7.51 (-0.61), CLLS: 35.73 (-0.65), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), PNR: 60.63 (+1.18), APOL: 13.12 (-0.26), DSKX: 3.39 (+0.15)
Critical Alerts For Palo Alto Networks, Intrexon, FireEye, Mylan and Kite Pharma Released By InvestorsObserver
PR Newswire - Wed Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for PANW, XON, FEYE, MYL and KITE.
FEYE: 46.89 (+1.20), KITE: 70.32 (-1.59), XON: 59.83 (-0.77), MYL: 57.09 (+0.74), PANW: 182.40 (-4.43)
NantKwest Surges As Biggest Biotech Market Cap IPO
at Investor's Business Daily - Tue Jul 28, 11:08AM CDT
NantKwest (NK) soared on its first day of trading, after raising $207 million in an upsized initial public offering. NantKwest is in the hot field of immunotherapy, which deploys the patient's own immune system to fight cancer and other diseases....
KITE: 70.32 (-1.59), NK: 35.78 (+1.14), ALXN: 201.73 (-1.82), RCPT: 227.77 (+0.61), AMGN: 169.92 (-2.82), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
Biotech IPO Boom Gaining Thrust With NantKwest Debut
at Investor's Business Daily - Fri Jul 24, 5:33PM CDT
A hot market for biotech IPOs is about to get hotter with the upcoming debut of NantKwest, a developer of cancer therapies that could set a record for market valuation. NantKwest (NK) will be the 51st initial public offering in the health care field...
BBP: 35.46 (-0.85), BIIB: 310.86 (-9.07), BBC: 35.81 (-0.86), ADRO: 26.34 (-0.24), KITE: 70.32 (-1.59), NK: 35.78 (+1.14), ALXN: 201.73 (-1.82), RCPT: 227.77 (+0.61), TEVA: 71.10 (-0.31), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
3 IPOs That Are Getting Strong Investor Attention
at Investor's Business Daily - Wed Jul 15, 11:48AM CDT
With strong investor demand for shares, ProNAi Therapeutics (DNAI) raised the expected price of its initial public offering, which is scheduled to price after the close Wednesday. ProNAi is among three of the eight IPOs out this week that are...
RPD: 24.61 (-0.41), CYBR: 58.28 (-1.55), KITE: 70.32 (-1.59), OLLI: 19.59 (-0.12), DNAI: 26.53 (-0.28), QLYS: 36.75 (-0.38), JUNO: 48.08 (-0.54)
'Fast Money' Recap: Netflix, Google, Other Tech Earnings to Watch
at The Street - Wed Jul 15, 4:00AM CDT
The trading panel discusses what to buy and what to avoid.
FB: 96.01 (+0.72), FBT: 124.21 (-2.39), XBI: 251.67 (-7.27), AMGN: 169.92 (-2.82), IBB: 375.98 (-6.86), INTC: 29.03 (+0.07), CELG: 132.89 (-2.53), NFLX: 106.61 (-0.29), SPY: 210.27 (+0.94), GILD: 116.69 (+3.62), KITE: 70.32 (-1.59), RCPT: 227.77 (+0.61), JUNO: 48.08 (-0.54), TWTR: 31.50 (-5.04), AAPL: 122.70 (-0.68), Z: 79.15 (-1.04)
Critical Alerts For Cliffs Natural Resources, JD.com, Kite Pharma, JetBlue and Amazon.com Released By InvestorsObserver
PR Newswire - Tue Jul 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CLF, JD, KITE, JBLU and AMZN.
AMZN: 527.05 (+1.02), KITE: 70.32 (-1.59), JBLU: 22.90 (+0.08), CLF: 2.89 (-0.08), JD: 32.92 (+0.44)
Trader's Notebook: Can Chevron Maintain Its High Yield?
at The Street - Tue Jul 14, 8:00AM CDT
Look under the hood when considering when to make a play for higher yielding names.
KITE: 70.32 (-1.59), CVX: 92.83 (+0.43)
5 Stocks Ready for Breakouts -- Must-See Charts
at The Street - Fri Jul 10, 8:35AM CDT
These stock charts look ready to break out and trade higher from current levels.
VSTM: 7.51 (-0.12), KITE: 70.32 (-1.59), GKOS: 32.10 (+1.33), AMRN: 2.21 (+0.06), CTCT: 24.79 (-0.42)
3 Biotech Stocks Working On CAR-T Immunotherapy You Ought To Watch
Todd Campbell, The Motley Fool - Motley Fool - Mon Jul 06, 12:02PM CDT
Source: Juno Therapeutics. Last week, Celgene Corp. shocked biotech investors when it agreed to pay $1 billion for $850 million worth of Juno Therapeutics ' stock and a handful of licensing rights, leaving Celgene with a 10% stake in the...
ZIOP: 12.45 (-0.19), KITE: 70.32 (-1.59), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
InsiderInsights.com Daily Round Up 7/2/15: NHF, VISI, NXRT, ATLS
InsiderInsights - at Seeking Alpha - Sat Jul 04, 11:54AM CDT
LBTYK: 48.60 (-0.09), TACO: 15.37 (+0.03), ATLS: 3.32 (+0.25), GIII: 68.92 (-0.42), VISI: 9.50 (-0.12), NXRT: 12.73 (-0.08), ALRM: 17.75 (+0.67), TRU: 24.92 (+0.32), W: 36.13 (-1.73), LVLT: 49.41 (-3.09), PDVW: 29.05 (-1.37), COF: 79.11 (+0.46), KITE: 70.32 (-1.59), APPF: 14.52 (-0.18), CPLA: 51.24 (+0.99), HRG: 13.99 (+0.32), JUNO: 48.08 (-0.54), TWTR: 31.50 (-5.04)
Kite Pharma Gains after Striking KTE-C19 Development Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 02, 4:00PM CDT
Kite Pharma (KITE) inks deal with The Leukemia & Lymphoma Society for the development of KTE-C19 in patients with refractory aggressive non-Hodgkin lymphoma.
BLUE: 156.39 (-3.93), KITE: 70.32 (-1.59), ADMS: 25.23 (-1.31), ACHN: 8.41 (unch)
Celgene: The Juno Therapeutics Deal Is Worth The Premium
LN Investors - at Seeking Alpha - Wed Jul 01, 3:04PM CDT
KITE: 70.32 (-1.59), AMGN: 169.92 (-2.82), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53), NVS: 103.81 (+1.02)
Kite Pharma and The Leukemia & Lymphoma Society(R) Enter Into Collaboration to Enhance the Development of KTE-C19 in Refractory Aggressive Non-Hodgkin Lymphoma and Launch CAR T-Cell Therapy Educational Programs
GlobeNewswire - Wed Jul 01, 7:00AM CDT
Kite Pharma, Inc., (Nasdaq:KITE) and The Leukemia & Lymphoma Society (LLS) announced today that they have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
KITE: 70.32 (-1.59)
'Fast Money' Recap: Greece's Uncertain Future Extends to U.S. Stocks
at The Street - Wed Jul 01, 4:00AM CDT
The trading panel discussed Puerto Rico, European stocks and whether Facebook will buy Twitter.
FIT: 44.66 (-0.81), SPY: 210.27 (+0.94), NKE: 114.39 (+0.92), KITE: 70.32 (-1.59), GILD: 116.69 (+3.62), FB: 96.01 (+0.72), DB: 33.46 (+0.22), GOOGL: 654.47 (-5.19), KORS: 39.59 (+0.17), TWTR: 31.50 (-5.04), AAPL: 122.70 (-0.68)
Juno-Celgene Deal Has Street Cautiously Optimistic
at Investor's Business Daily - Tue Jun 30, 3:58PM CDT
Shares of biotech startup Juno Therapeutics rose as much as 29% Tuesday, and closed up 15%, as analysts weighed in on its $1 billion deal with Celgene announced late Monday. Celgene (CELG) agreed to pay $150 million upfront and buy 9.1 million Juno...
BLUE: 156.39 (-3.93), KITE: 70.32 (-1.59), CLLS: 35.73 (-0.65), JUNO: 48.08 (-0.54), CYAD: 57.09 (+0.25), CELG: 132.89 (-2.53)
Bit of a Bounce Brings Sigh of Relief
at The Street - Tue Jun 30, 3:12PM CDT
Uncertainty on Greece prevails, but it could have been worse.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)
A Good Cleanout Is Refreshing
at The Street - Tue Jun 30, 12:57PM CDT
And so is a shift in emotions.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)
Why Juno Therapeutics Stock Soared Today
George Budwell, The Motley Fool - Motley Fool - Tue Jun 30, 10:35AM CDT
What : Shares of the clinical-stage biopharma Juno Therapeutics jumped by 33% on exceptionally high volume today after the company announced a 10-year licensing agreement with Celgene Corp. for its CAR-T and TCR drug development platform. Per...
NBL: 36.08 (+0.58), KITE: 70.32 (-1.59), AZN: 32.94 (+0.13), JUNO: 48.08 (-0.54), CELG: 132.89 (-2.53)
I Don't Believe This Correction Is Over
at The Street - Tue Jun 30, 9:20AM CDT
There just is no certainty and there's very little trust.
SGYP: 8.12 (-0.12), NFLX: 106.61 (-0.29), BLUE: 156.39 (-3.93), AMZN: 527.05 (+1.02), TSLA: 264.79 (-0.03), KITE: 70.32 (-1.59), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), EGRX: 92.44 (-0.40)
Premarket Gainers / Losers as of 9:15 am
Seeking Alpha - at Seeking Alpha - Tue Jun 30, 8:19AM CDT
FIT: 44.66 (-0.81), PIRS: 3.12 (-0.08), KITE: 70.32 (-1.59), SRPT: 31.50 (-0.53), WSH: 46.60 (+0.41), CALA: 7.51 (-0.61), CLLS: 35.73 (-0.65), LBIO: 8.54 (-0.27), JUNO: 48.08 (-0.54), PNR: 60.63 (+1.18), APOL: 13.12 (-0.26), DSKX: 3.39 (+0.15)
(0)
(0)